A pair of late-stage trials found that Eli Lilly’s experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday, intensifying the company’s race with Novo Nordisk to develop longer-acting insulins.
Related Posts
Add A Comment